Factors Associated With Pharmacological and Non-pharmacological Treatments Adherence in Patients With Borderline Personality Disorder in Iran

Motahareh Sadat Mirhaj Mohammadabadi  
Iran University of Medical Sciences

Homa Mohammadasadeghi  
Iran University of Medical Sciences

Mehrdad Eftekhar Adrebili  
Iran University of Medical Sciences

Zahra Partovi Kolour  
Iran University of Medical Sciences

Fatemeh Kashaninasab  
Iran University of Medical Sciences

Mohammadreza Shalbafan (✉ Shalbafan.mr@iums.ac.ir)  
Psychosocial Health Research Institute, Iran University of Medical Sciences

Research Article

Keywords: Borderline personality disorder, treatment outcome, pharmacotherapy, psychotherapy

Posted Date: January 3rd, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1202989/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Background

Borderline personality disorder is a major mental illness characterized by a sustained relationship instability, impulsive behavior and intense affects. Adherence is a complex behavior, from minor refusals of treatment to inappropriate use of health services or even abandonment of treatment, which can be affected by various factors. Therefore, the present study aimed to investigate the factors affecting pharmacological and non-pharmacological adherence in patients with borderline personality disorder referred to an outpatient referral clinic in Tehran, Iran.

Methods

The study was a retrospective cohort. The files of patients with borderline personality disorder referred to the outpatient clinic of the Tehran Psychiatric Institute were reviewed as the first step. In the next step, we contacted the patients and asked them to fill out the questionnaires. Data were collected using the Drug Attitude Inventory (DAI) questionnaire and a researcher made questionnaire to determine the attitude of patients toward pharmacological and non-pharmacological treatment and therapeutic adherence. After collecting data, patients' therapeutic acceptance was divided into three groups: poor, partial, good compliance. The data were analyzed by SPSS software version-22.

Results

Ninety-four patients were involved in the study and fifty four of them were women. In terms of psychotherapy adherence, patients with higher education and hospital admission history have better compliance. Medication attitudes were negative in 54 patients (57.4%), while 40.4% of them stated that psychotherapy or counselling did not help their condition and showed a negative attitude toward non-pharmacological treatment. Additionally, psychotherapy good adherence of the patients (44.7%) was higher than medication good adherence (31.9%). The most common reasons for discontinuation of treatment were medication side effects (53.1%), dissatisfaction with the therapist (40.3%) and then fear of medication dependence (40%). The results showed no relationship between other demographic factors and treatment adherence.

Conclusions

Results of the current study show that attitude toward psychotherapy is more positive than pharmacotherapy. In addition, according to the results, working on changeable factors such as patients’ fear of dependence to medication, dissatisfaction with the therapist, and medication side effects may improve patients' treatment adherence.
Borderline personality disorder (BPD) is characterized by severe instability in impulsive feelings, identities, relationships, and behaviors (1). Patients with BPD are hypersensitive to emotional stimuli due to abnormal activity in the brain's prefrontal areas during stimulus processes (2). BPD is a major mental illness that has a prevalence of approximately 1-3% among general population. With the constant change in the instability of relationships, the creation and regulation of impulses and the sense of life were determined (3). BPD is a severe disorder that accounts for 20 to 40% of psychiatric admissions, and it is estimated that 84% of patients show suicidal behaviors, and 8% of them die due to suicide (4,5). BPD causes many problems for the patient and the community. The repeated and severe damages caused by this disorder affect the entire life of an individual, including occupational problems, being a dropout, and disruption of relationship with friends and colleagues, family members, failure in marriage and high-risk and unstable sexual relations. Almost 11-69% of patients are substance users, 22% of these patients suffer from alcoholism and 25 to 50% of female prisoners are patients with BPD (6-11).

An accurate prevalence rate is not available in Iran. Due to the cultural and civil changes in recent years in Iran, and the existence of religious thoughts in the Iranian community and families, in most cases, the behaviour of patients with borderline personality disorder are contrary to social norms and severely complicating among Iranian society (12,13).

In 2017 Little et al. showed that behavioral therapy alters supportive relationships, improves self-efficacy, and alters individual attitudes (14). In a study by Bellino et al., patients with more severe BPD and higher levels of symptoms such as fear of abandonment, emotional instability, and identity showed a better chance of combining psychotherapy with fluoxetine (15). Although psychotherapy is still the first line of treatment for patients with BPD, medications are commonly prescribed for them. The use of antidepressants has decreased, and mood stabilizers and second-generation antipsychotics have increased (16).

Adherence is a complex behavior, from minor refusals of treatment to inappropriate use of health services or even abandonment of therapy, which can be affected by various factors. These factors are often patient-dependent (17). Rejection is often associated with irrational fears and misjudgments, and the most common cause is fear of medication dependence. Various studies have been performed on patients with personality disorders, schizophrenia and bipolar showed that one of the critical issues in the treatment is the acceptance of treatment by patients. Due to the prevalence of BPD and the need for long-term pharmacological and non-pharmacological treatment, the high cost of treatment imposed on the health care system and the fact that no study was conducted in Iran, it seems necessary to evaluate the medication and non-medication adherence in these patients. Hoping that by working on changeable factors, patients’ adherence and, consequently, their function improves and the recurrence of symptoms and re-admission will be reduced.

In the present study, we investigate the factors of rejection and reasons for discontinuation of treatment to provide a way to improve adherence in these patients and to introduce practical methods into the clinical practice of therapists in future studies.
Methods

Study design & Participants

The study was conducted as a retrospective cohort. In this study, the files of patients with BPD who were referred to the outpatient adult psychiatric clinic of Tehran Psychiatric Institute, Tehran, Iran in April of 2014 to April 2019 were reviewed as the first step. Patient information including name, gender, age, occupation, education, marital status, family history of psychiatric illness, type of treatment, history of substance use, history of hospitalization, history of suicide and self-harm, comorbidity and medication side effects based on the files, was recorded. In the next step, patients were contacted to collect the information, including receiving or not receiving medical or non-pharmacological treatment, last referral date, confirmation of demographic data, current life status (alone, with family), suicide and self-harm, financial status, legal issues, medication side effects, and location (far or close to the treatment center). In addition, they were asked to fill out the Drug Attitude Inventory (DAI) questionnaire and a researcher made questionnaire to determine the attitude of patients toward pharmacological and non-pharmacological treatment and therapeutic adherence. Patients who did not respond were called three times within a week, and if they did not respond, they were given a message and excluded from the study if they did not respond again.

Instruments

In this study, in addition to demographic items, two questionnaires were used. The first questionnaire, was DAI-10 based that evaluate attitude of patients toward medication with 10 yes-no questions and higher total score between +10 and -10 shows more positive attitude. Shariati et al. confirmed psychometric properties of the Persian version of the scale (19). They reported Test-retest reliability was 0.805 and Cronbach's α 0.787. Concurrent validity between DAI-10 score and Medication possession rate (MPR) at the study time was 0.676, and positive predictive value of DAI-10 score for medication compliance at assessment time was about 88.9%. The spearman correlation coefficient between the two tests was 0.822 (95% confidence interval (CI): (0.652 - 0.901). They also reported cut off point +1, with the specificity of 81.5% and sensitivity of 89.1%. (19).

The second questionnaire was a researcher made questionnaire to determine attitude of patients toward pharmacological and non-pharmacological treatment and therapeutic adherence. This questionnaire consisted of 17 questions which was validated by eight psychiatric faculty members of Iran University of Medical Sciences. To standardize and validate the questionnaire, qualitative assessment was done using an expert panel and quantitative assessment was done using content validity ratio (CVR) and content validity index (CVI) (20). According to the overall CVR (0.75<) and the CVI (0.79<), the questionnaire had content validity. This questionnaire was divided into two parts. The first part, which included questions (1-6), was filled by all 94 patients, and the second part, (questions 7-17) was filled by 64 patients with moderate or poor drug compliance.
Finally, based on the data, the patients' current medical acceptance was evaluated by the researcher, and according to the Medication possession rate (MPR), patients were divided into three groups: poor, good, and partial pharmacological adherence. Based on MPR more than 80% compliance equal good adherence, between 50 to 80% equal partial adherence and less than 50% equal poor adherence. The MPR represents the proportion of days of medication supply in a specified time period, in our study last month, and is given by the sum of days divided by the number of days within the time interval (21).

**Statistical analysis**

Data were analyzed by IBM SPSS STATISTICS 22 (IBM Inc, New York, USA). Data are presented as number and percent and compared between groups by chi square and t-test. Patients' outcome was statistically analyzed based on variables using Kaplan method. Regression model has been used to investigate the effect of determining factors. P values less than 0.05 were assumed as statistically significant.

**Results**

Ninety-four patients were involved in the study; the mean age was 33.6, 54 (57.4%) were female, and the others were male. Demographic data and psychiatric history of the participants are shown in table 1&2.

Answers to the researcher made questionnaire about the attitude of patients toward pharmacological and non-pharmacological treatment and therapeutic adherence are shown in table 3 and reasons for poor/partial drug compliance are shown in table 4.

Moreover, regarding the DAI-10 total score, 54 patients (57.4%) had a negative attitude, and 40 patients (42.6%) had a positive attitude towards the medication.

There was no relationship among gender (P=0.335), job (P=0.16), education (P=0.710), marital status (P=0.378), history of psychiatric hospitalization (P=0.812), history of self-injury (P=0.833), suicide history (P=0.541), history of substance use (P=0.857), comorbidity with psychiatric disorders (P=0.630), family history of mental illness (P=0.778) and medication adherence.

There was no relationship among gender (P=0.626), job (P=0.303), marital status (P=0.759), history of self-injury (P=0.364), suicide history (P=0.649), history of substance use (P=0.577), comorbidity with psychiatric disorders (P=0.230), family history of mental illness (P=0.524) and type of medication used (P=0.063) and psychotherapy adherence. There was a statistical significant difference between education level and psychotherapy adherence (P=0.029). The best adherence to psychotherapy was obtained in postgraduate education (with 66% good adherence among this subgroup) and the worst medication adherence in undergraduate education (with 22% good adherence among this subgroup) (P=0.04). In terms of history of psychiatric hospitalization, there was a significant difference between people with different psychotherapy adherence (P=0.01); those who had a history of hospitalization had better adherence to psychotherapy than non-hospitalized patients (66% vs. 36.9% of the relevant subgroup).
Regression analysis between medication adherence and significant variables, patients' belief that their disorder is treatable, lack of treatment disrupts their lives and those around them are inversely related to poor and relative medication adherence. Patients with a negative medication attitude are 1.3 times more likely to have poor medication adherence and 2.8 times more likely to have relative medication adherence. Regression analysis between psychotherapy adherences and significant variables showed, patients with postgraduate education are 2.2 times more likely to have good psychotherapy adherence and patients with diploma education are 1.2 times more likely to have poor psychotherapy adherence.

There was a significant relationship between attitudes toward medication and the belief that "lack of treatment disrupts relationships with others". 87.5% of patients with a positive attitude stated that lack of treatment could disrupt their relationships with others. 81.5% of patients who disagreed with this view had a negative medication attitude (P=0.03). There was a significant relationship between attitudes toward medication and the belief that "their disorder can be treated". 95% of patients with a positive medication attitude believed that their disorder could be treated (P=0.001). 72.2% of patients who had a negative attitude toward medication, believed that the medication side effects had interrupted their treatment (P=0.022).

**Discussion**

The aim of this study was to determine the factors contributing to the pharmacological and non-pharmacological adherence in 94 patients with BPD, who were referred to the outpatient clinic of Tehran Psychiatric Institute. The results of this study showed that in gender, occupation, education, marriage, history of psychiatric hospitalization, history of self-harm and suicide attempt and history of substance use were not significantly different in people who had good, bad and relative adherence to medication. However, education and history of hospitalization were significantly different in patients with good, bad and relative adherence to psychotherapy. Also the analysis showed that there was no significant difference between gender, occupation, education, marriage, history of psychiatric hospitalization, history of self-harm and suicide and history of drug use and adherence to medication.

In 2020, Zarei et al. examined the improvement of BPD at different time intervals of transference-focused treatment. Their findings showed that gender, occupation, education, marriage, history of psychiatric hospitalization and history of self-harm were not significantly different in people with different adherence to treatment, which was consistent with our results (22). In another study, there was no significant difference between history of self-harm, substance use, psychiatric comorbidity, history of psychiatric illness and type of medication and medication adherence that was consistent with our results (23).

Soltaninejad et.al showed that self-injury, substance use, psychiatric comorbidity, history of psychiatric illness and type of pharmacotherapy were not significantly different in groups with different adherence to medication that was consistent with our results (24).

The findings of our study showed better attitude toward psychotherapy, negative attitude toward medication, fear of medication dependence were the most common reason for poor adherence. In 2019,
Timäus et al. conducted a study to evaluate the pharmacological treatment, medication and psychotherapy adherence in patients with BPD. In this study, discontinuation of treatment due to dissatisfaction with the physician, lesser education, history of psychiatric hospitalization and discontinuation of treatment due to the high cost of psychotherapy were seen significantly different among individuals with different psychotherapy compliance. But in other variables such as gender, occupation, education, marital state, history of psychiatric hospitalization, history of self-injury and history of substance use were not significantly difference among people with different medication and psychotherapy adherence; all of these results were similar to our study (25). In general, demographic factors, history of self-harm and suicide, history of substance use and comorbidity did not affect patient's adherence in our study.

**Limitations**

There were several limitations; the first one was the small sample size. Also, some inaccurate recording of documents and the lack of facilities to follow up patients and failure to assess the severity of the disorder was other limitation. It is suggested considering these limitations for future studies.

**Conclusion**

In conclusion, working on changeable factors such as patients fear of dependence to medications, dissatisfaction with their doctor, medication side effects and patients' attitude toward medication, belief in the curability of the disorder, and belief in the negative impact of the treatment on the person's life increase the patients' adherence to treatment, therefore their function and interpersonal relationships improve.

**Abbreviations**

Borderline personality disorder: BPD; Drug Attitude Inventory: DAI; Medication possession rate: MPR; content validity ratio: CVR; content validity index: CVI

**Declarations**

**Funding**

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

**Competing interests**

The authors have no conflicts of interest to report.

**Availability of data and materials**
The dataset used and analyzed during the current study can be shared by the corresponding author upon reasonable request.

**Authors’ contributions**

Conceptualization and design: MSMM, HM, MEA and MS; Data gathering: MSMM, ZPT, FK Initial draft preparation: MSMM, HM and MS; Editing & review: All authors. All authors read and approved the final manuscript.

**Ethics approval**

In this study, no intervention was performed on patients. If a person refused to participate in the study, he/she wouldn't be deprived of any medical services. All personal information remained confidential. The study protocol was approved by Institutional Review Board of Iran University of Medical Sciences (Ethic code: IR.IUMS.FMD.REC.1397.193)

**Consent to participate**

Online informed consent was taken from the patients.

**Consent for publication**

Not applicable

**Acknowledgment**

We wish to thank the outpatient psychiatric clinic of Tehran Psychiatric Institute, which helped us complete this dissertation.

**References**

1. Falconer CJ, Cutting P, Bethan Davies E, Hollis C, Stallard P, Moran P. Adjunctive avatar therapy for mentalization-based treatment of borderline personality disorder: a mixed-methods feasibility study. *Evid Based Ment Health*. 2017 Nov;20(4):123-127.

2. Lischke A, Herpertz SC, Berger C, Domes G, Gamer M. Divergent effects of oxytocin on (para-) limbic reactivity to emotional and neutral scenes in females with and without borderline personality disorder. *Soc Cogn Affect Neurosci*. 2017 Sep 19

3. Bassir Nia A, Evel eth MC , Gabbay JM, Hassan YJ , Zha ng B, odriguez MM Perez-R Past, present, and future of genetic research in borderline personality disorder. *Curr Opin Psychol*. 2017 Sep 12;21:60-68.

4. Kaplan BJ. Kaplan and Sadock's Synopsis of Psychiatry: Behav ional Sciences/Clinical Psychiatry. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins; 2016.
5. Pompili M, Girardi P, Ruberto A, Tatarelli R. Suicide in borderline personality disorder: A meta-analysis. Nordic Journal of Psychiatry. 2005; 59(5):319-24.

6. Bradley R, Conklin CZ., Westen D. Borderline personality disorder. In: O’Donohue W, Fowler K, Lilienfeld S, (Eds.). Personality disorders: Toward the DSM-V. Thousand Oaks, CA: Sage; 2007. P.167-201.

7. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. USA: American Psychiatric Publishing. 2013. P.991.

8. Gunderson JG, Links P. Borderline Personality Disorder: A clinical guide. 2nd ed. Washington DC: American Psychiatric Press, Inc: 2008.P.416.

9. Sansone RA, Sanson LA, Borderline personality and criminality. Psychiatry (Edgmont) 2009;6(10):16-20.

10. Keuroghlian AS, Zanarini MC. Lessons learned from longitudinal studies of personality disorders, Personality disorders: Toward theoretical and empirical integration in diagnosis and assessment. American Psychological Association 2015:145-61.

11. Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB. The subsyndromal phenomenology of borderline personality Disorder: A 10-year follow-up study. Am J Psychiatry 2007;164(6):929-35.

12. Mokhtari S, Shariat SV, Ardebili ME, Shalbafan M. Iranian students' attitudes toward premarital sex, marriage, and family in different college majors. J Am Coll Health. 2020 Jul 16:1-9.

13. Eissazade, N., Hemmati, D., Ahlzadeh, N., Shalbafan, M., Askari-Diarjani, A., Mohommadsadeghi, H., & Pinto da Costa, M. (2021). Attitude towards migration of psychiatric trainees and early career psychiatrists in Iran. BMC medical education, 21(1), 1-7.

14. Little H, Tickle A, das Nair R. Process and impact of dialectical behaviour therapy: A systematic review of perceptions of clients with a diagnosis of borderline personality disorder. Psychol Psychother. 2017 Oct 16.

15. Bellino S, Bozzatello P, Bogetto F. Combined treatment of borderline personality disorder with interpersonal psychotherapy and pharmacotherapy: predictors of response. Psychiatry Res. 2016 Jun 30;240:151-156

16. Starcevic V, Janca A. Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism. Curr Opin Psychiatry. 2017 Oct 11

17. TANESI, Patrícia Helena Vaz; YAZIGI, Latife; FIORE, Maria Luiza de Mattos and PITTA, José Cássio do Nascimento. Adherence in the treatment of borderline personality disorders. Estud. psicol. (Natal) [online]. 2007, vol.12, n.1, pp.71-78.

18. Ali Sharifi, Amir Shabani, Masoud Ahmadzad-As. The Pattern of Adherence in Patients with Bipolar I Disorder, an Eight Weeks Study. IJPBS 2009, 3(2): 39-43.

19. Asadi, M., Rashedi, V., Khademoreza, N., Seddigh, R., Keshavarz-Akhalghi, A. A., Ahmdkhaniha, H., ... & Shalbafan, M. (2021). Medication Adherence and Drug Attitude Amongst Male Patients with the
Methamphetamine-Induced Psychotic Disorder After Discharge: A Three Months Follow Up Study. Journal of Psychoactive Drugs, 1-7.

20. Zamanzadeh V, Ghahramanian A, Rassouli M, Abbaszadeh A, Alavi- H. Design and implementation content validity Study: development of an instrument for measuring patient-centered communication. J Caring Sci. 2015;4(5):165–78.

21. C.M. Sperber, S.R. Samarasinghe, G.P. Lomax, An upper and lower bound of the medication possession ratio, Patient Prefer. Adherence. 11 (2017) 1469–1478.

22. zarei G, Rahimian Boogar I, Moazedian A, jahan A. Improvement of borderline personality disorder at different time frames of transference focused psychotherapy: a case report. Stud Med Sci. 2020; 31(4) :255-266.

23. Zargar, Y., Sajadi, S. F., Mehrabizadeh Honarmand, M., & Arshadi, N. (2014). Validation of the borderline personality features scale for children on students in Shiraz. The Journal of Urmia University of Medical Sciences, 25(4), 338-352.

24. zarei G, Rahimian Boogar I, Moazedian A, jahan A. Improvement of borderline personality disorder at different time frames of transference focused psychotherapy: a case report. Stud Med Sci. 2020; 31(4) :255-266.

25. Soltaninejad, Abdollah, Ashtiani Ali Fathi, Khodabakhsh Ahmadi, Emad Yahaghi, Alireza Nikmorad, Rohollah Karimi, And Atefe Abdolmanafii. "Structural equation model of borderline personality disorder, emotion-focused coping styles, impulsivity and suicide ideation in soldiers." (2013): 176-182.

26. Timäus, C., Meiser, M., Bandelow, B., Engel, K. R., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019). Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice. BMC psychiatry, 19(1), 1-11.

Tables

Table 1. Demographic data of participants
| Frequency (%) | Variable       |
|--------------|---------------|
| 41 (43.6)    | Employees     |
| 10 (10.6)    | College students |
| 43 (45.7)    | Unemployed    |
| 21 (22.3%)   | Under diploma |
| 43 (45.8)    | Diploma and higher |
| 21 (22.3%)   | Bachelor’s degree |
| 9 (9.6%)     | Master’s degree or higher |
| 49 (52.1%)   | Single        |
| 32 (34%)     | Married       |
| 12 (12.8%)   | Divorced      |
| 46 (48.9%)   | Poor          |
| 18 (19.1%)   | Moderate      |
| 30 (31.9%)   | Good          |
| 21 (22.3%)   | Poor          |
| 31 (33%)     | Partial       |
| 42 (44.7%)   | Good          |

Table 2. Participants’ psychiatric history

| Frequency (%) | History                        |
|--------------|--------------------------------|
| 21 (22.3%)   | Psychiatric Hospitalization    |
| 34 (36.2%)   | Family history of psychiatric illness |
| 15 (16%)     | Legal problems                 |
| 30 (31.9%)   | Self-injury                    |
| 40 (42.6)    | Suicide attempt                |
| 42 (44.7%)   | Illegal substance use          |

Table 3. Insight and tendency for treatment (First part of the questionnaire)
| Frequency (%) | Answer | Questions                                                                 | Number |
|---------------|--------|---------------------------------------------------------------------------|--------|
| 65(69.1)      | Yes    | I am sick and need treatment                                              | 1      |
| 29(30.9)      | No     |                                                                           |        |
| 59(62.8)      | Yes    | Lack of treatment can disrupt my life and the lives of those around me     | 2      |
| 35(37.2)      | NO     |                                                                           |        |
| 67(71.3)      | Yes    | Lack of treatment can cause problems in my relationships with others      | 3      |
| 27(28.7)      | No     |                                                                           |        |
| 73(77.7)      | Yes    | My illness is treatable                                                   | 4      |
| 21(22.3)      | No     |                                                                           |        |
| 49(52.1)      | Yes    | Medication has not helped my condition                                    | 5      |
| 45(47.9)      | No     |                                                                           |        |
| 38(40.4)      | Yes    | Psychotherapy or counselling did not help my condition                    | 6      |
| 56(59.6)      | No     |                                                                           |        |

Table 4. Reasons for poor/partial drug compliance (Second part of the questionnaire)
| Frequency (%) | Answer | Questions                                                                 | Number |
|---------------|--------|---------------------------------------------------------------------------|--------|
| 12(18.8)      | Yes    | I did not continue the treatment due to the cost of the doctor's visit.   | 1      |
| 52(18.2)      | NO     |                                                                           |        |
| 10(15.6)      | Yes    | I did not go to another center due to travel expenses.                    | 2      |
| 54(84.4)      | NO     |                                                                           |        |
| 26(40.6)      | Yes    | Because I was not satisfied with my doctor, I did not see him again.      | 3      |
| 38(59.4)      | NO     |                                                                           |        |
| 18(28.1)      | Yes    | Because I could not easily make an appointment, I did not return.         | 4      |
| 46(71.9)      | NO     |                                                                           |        |
| 12(18.8)      | Yes    | The misbehavior of others and their talk about my illness caused me to stop taking my medication. | 5      |
| 52(81.3)      | NO     |                                                                           |        |
| 34(53.1)      | Yes    | Drug side effects caused me to stop my medication.                        | 6      |
| 30(46.9)      | NO     |                                                                           |        |
| 13(20.3)      | Yes    | I stopped taking the medicine because of the cost of the medicine.       | 7      |
| 51(79.7)      | NO     |                                                                           |        |
| 21(32.8)      | Yes    | Because the duration of my medication was long, I did not take any more medications. | 8      |
| 43(67.2)      | NO     |                                                                           |        |
| 26(40.6)      | Yes    | I stopped taking it for fear of drug dependence.                         | 9      |
| 38(59.4)      | NO     |                                                                           |        |
| 21(32.8)      | Yes    | I stopped psychotherapy due to the cost of psychotherapy.                | 10     |
| 43(67.2)      | NO     |                                                                           |        |
| 13(20.3)      | Yes    | For a long time, my psychotherapy was the reason for interrupting psychotherapy sessions | 11     |
| 51(79.4)      | NO     |                                                                           |        |